GoTo Raises Capital Through Dilutive Shares and Warrants
GoTo is raising NIS 9.7 million in cash, but the share, warrant, and management-equity package resets the common shareholder layer before the operating improvement proves independent cash flow. The raise is a real liquidity source, with a real equity cost.
GoTo is not only adding cash to the balance sheet. The financing round expected to bring in about NIS 9.7 million also reprices the existing shareholder layer, because it comes with shares, warrants, and an equity-compensation package for management and employees. The cash matters: it is larger than the company's cash balance at the end of the first quarter, and it comes right after the bank granted a covenant waiver and set a new 2026 covenant ladder. The equity price matters just as much: assuming full exercise of the warrants issued in the round, the voting rights allocated to the investors equal about 55.9% of the pre-round voting rights. On top of that sits an RSU and option layer for officers and employees, with fair value of about NIS 2.6 million, which adds another future claim on equity without bringing in additional cash. The follow-up question is therefore not only whether the round is approved, but whether the new cash reduces the need for further dilution through covenant compliance, operating cash flow, and growth that stops requiring outside funding.
The Raise Is Large for the Company, Not Only for the Cash Balance
The financing round is a clear liquidity source: about NIS 9.722 million in cash against the issuance of 2.430555 million shares and 2.430555 million warrants. Compared with a cash balance of NIS 8.23 million at the end of March 2026, that amount can materially change the company's immediate room for maneuver. Compared with a market cap of about NIS 30.5 million at the end of May 2026, it is also a major equity event, not a marginal add-on.
| Round component | Amount or quantity | Meaning for existing shareholders |
|---|---|---|
| Cash to the company | About NIS 9.722 million | Strengthens liquidity while operating cash flow is still not independent |
| Shares issued to investors | 2.430555 million | Basic addition of about 28% relative to the existing share count |
| Warrants issued to investors | 2.430555 million | Additional potential dilution if exercised |
| Shares and warrants together | 4.861110 million | About 55.9% of pre-round voting rights assuming full exercise |
| Current market cap | About NIS 30.5 million | The raise equals roughly one third of market cap before future warrant exercise |
The detail that sharpens the price is not only the size of the issuance, but its terms. The economic value of the issued share, after deducting the economic value of the warrant, reflects a discount of about 25.3% to the share price at the end of the trading day before the board's first decision on the allocations, which was NIS 4.54. In other words, the company is buying liquidity through an equity price below the relevant market price at the decision date, and through a warrant that gives new investors additional participation if the story improves.
That structure is typical for a small company with an evident financing need: new investors are compensated for risk through price and optionality, and the company receives cash that reduces near-term pressure. What is unusual here is the size of the package relative to the existing shareholder layer. In a round like this, the economic question is not only how much cash enters the company, but how much of any future improvement remains with the shareholders who were already there.
Management Equity Adds a Separate Dilution Layer
The financing round is not the only dilution layer created around the quarter. On March 29, 2026, the board approved an allocation to the CEO of 100 thousand options at an exercise price of about NIS 3.1, vesting over two years. On the same day, it approved 131,250 RSUs for the chairman and 414,414 RSUs for the CEO, up to 545,664 shares with no exercise payment, vesting over one year. It also approved 389 thousand options for employees and managers, also at an exercise price of about NIS 3.1, with part vesting over one year and part over two years.
The fair value of these packages totals about NIS 2.574 million: about NIS 164 thousand for the CEO options, about NIS 1.82 million for the chairman and CEO RSUs, and about NIS 590 thousand for the employee and manager options. In the first quarter, the company already recorded NIS 916 thousand of share-based payment expense. This is not a cash outflow, so it does not immediately hurt liquidity, but it does move part of the future upside to management and employees.
There is also a constructive reading: a company in a stabilization phase needs to retain management and employees, and equity compensation can align incentives when cash is expensive. The more cautious reading is that existing shareholders now face two parallel claims on equity: new investors bringing cash at a discount and with warrants, and management and employees receiving options and RSUs while the company still has to prove independent cash generation.
The Bank Explains Why This Liquidity Is Not Optional
The need for the round becomes clearer through the financial covenants. GoTo committed to a tangible-equity-to-tangible-balance-sheet ratio of at least 20% from the end of 2025, did not meet that covenant, and received a bank waiver for December 31, 2025. After the waiver, the bank set a new ladder: 2% for the first quarter of 2026, 15% for the second and third quarters, and 20% from the fourth quarter onward. At the same time, the bank-loan balance was classified as short term.
That means the new cash is not just growth financing. It is part of a structure that lets the company move through a year in which consolidated equity improved in accounting terms, while operating cash flow is still negative and bank debt remains a central line item. The company notes that its 24-month cash-flow forecast did not include the expected raise because it had not yet been approved by shareholders, and management believes available cash balances will allow the company to meet its obligations over the foreseeable period. That is an important counterpoint: the filing does not present the round as an immediate survival condition.
Still, the existence of a round of this size, alongside a bank waiver and rising covenant steps through the year, shows that the company needs an equity layer to turn operating improvement into a more stable financing position. If the raise is approved and the cash enters the company, GoTo gains room to operate. If operating improvement does not move into positive cash flow and easier covenant compliance, shareholders will have paid dilution for time, not for a full solution.
What the Next Quarters Need to Prove
The current read is clear: the raise is economically justified as a liquidity source, but it changes the distribution of value in the company. Existing shareholders receive a company with more cash and likely better bank flexibility, in exchange for a smaller share of future improvement. This cannot be read only through the NIS 9.7 million headline, because the shares, warrants, and management equity are part of the same price.
The first proof point is shareholder approval and actual closing of the round. After that, two numbers will decide whether the dilution bought a real improvement: compliance with the 15% tangible-equity-to-tangible-balance-sheet ratio in mid 2026, and operating cash flow that starts to show that growth in leasing, the fleet, and Trinity is not leaning again on another raise. If those two points improve, the dilution will look like the cost of moving into a more stable stage. If not, the round will become another layer in a capital structure that keeps transferring value from existing owners to new financiers.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.